Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRN-300 Alone and in Combination with Paclitaxel in Recurrent Ovarian and Related Cancers
NCT04711161Phase 1Suspended
- Sponsor
- Green3Bio
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GRN-300 in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Green3Bio. Primary endpoints: Maximum Tolerated Dose at 24 months, Recommended Phase 2 Dose at 24 months and 1 more. Started Dec 2020; status: suspended.
02
Drugs
GRN-300
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT04711161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711161.